Resúmenes Epistemonikos

← vista completa

Efectos de la dieta mediterránea en el tratamiento de la artritis reumatoide

Effects of Mediterranean diet on the treatment of rheumatoid arthritis

Abstract

INTRODUCTION It has been suggested that environmental and lifestyle factors might contribute to the severity and progression of inflammation in rheumatoid arthritis. An intervention generating high interest due to its supposed anti-inflammatory properties is the Mediterranean diet.

METHODS We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach.

RESULTS AND CONCLUSIONS We identified seven systematic reviews including four primary studies, of which only one corresponded to a randomized trial. We concluded Mediterranean diet may make little or no difference in pain or disease activity and may slightly increase weight in rheumatoid arthritis patients, but the certainty of the evidence is low. On the other hand, it was not possible to clearly establish whether Mediterranean diet has any effect on functionality, morning stiffness or quality of life as the certainty of the existing evidence has been assessed as very low.

Problem

Rheumatoid arthritis is a chronic autoimmune disease whose etiology is not fully known. There are important variations in its frequency, which cannot only be attributed to genetic or racial factors, so it has been suggested that environmental factors, such as tobacco use and diet might contribute to both the development and the severity of the disease [1].
Moreover, the Mediterranean diet has beneficial effects in the prevention and treatment of various health conditions, which are mediated by various mechanisms, such as increasing antioxidant levels, modifying intestinal flora, promoting an anti-inflammatory lipid profile (omega 3: omega 6 ratio) and possibly decreasing inflammation in other ways [2]. Its anti-inflammatory properties have generated a particular interest in its use as part of the treatment of rheumatoid arthritis, however, if this really translates into a relevant clinical effect is a matter of controversy.

Methods

We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others, to identify systematic reviews and their included primary studies. We extracted data from the identified reviews and reanalyzed data from primary studies included in those reviews. With this information, we generated a structured summary denominated FRISBEE (Friendly Summary of Body of Evidence using Epistemonikos) using a pre-established format, which includes key messages, a summary of the body of evidence (presented as an evidence matrix in Epistemonikos), meta-analysis of the total of studies when it is possible, a summary of findings table following the GRADE approach and a table of other considerations for decision-making. 

Key messages

  • The Mediterranean diet may make little or no difference in pain and disease activity for patients with rheumatoid arthritis (low certainty evidence). 
  • We are uncertain whether Mediterranean diet improves functionality, morning stiffness and quality of life in rheumatoid arthritis as the certainty of the evidence has been assessed as very low. 
  • Mediterranean diet may slightly increase weight among rheumatoid arthritis patients (low certainty evidence).

About the body of evidence for this question

What is the evidence.
See evidence matrix  in Epistemonikos later

We found seven systematic reviews [1], [2], [3], [4], [5], [6], [7] which included four primary studies, reported in six references [8], [9], [10], [11], [12], [13] of which only one was a randomized trial [8]. The information provided by the observational studies did not increase the level of certainty of the evidence, nor did add new relevant information. Therefore the table presented and the summary is based on the only randomized trial. 

What types of patients were included*

The trial was conducted in Sweden [8] and included 51 patients, mostly women (82.3%), with rheumatoid arthritis diagnosed by criteria ACR 1987, with at least two years from diagnosis and controlled disease according to the clinician criteria at randomization. The trial excluded patients who already had a vegetarian or Mediterranean diet, with high doses of corticosteroids, or recent adjustments in therapy.

What types of interventions were included*

The trial [8] evaluated a Mediterranean diet high in oils for 12 weeks in the intervention group, compared to Western diet in the control group.

The intervention was conducted in two stages with three weeks of education and diet in the hospital, followed by nine weeks of strict clinical follow-up where the food included in the diet was provided.

What types of outcomes
were measured

The trial [8] evaluated multiple outcomes, which were grouped by the systematic reviews as follows:

  • Pain (visual analogue scale, VAS)
  • Functionality (Health Assessment Questionnaire, HAQ)
  • Morning stiffness (minutes)
  • Activity Score (Disease Activity Score, DAS 28)
  • Vitality (SF-36)
  • Weight (kg) at week 12 of the intervention. 
  • Inflammatory parameters (C reactive protein, CRP) 

* The information about primary studies is extracted from the systematic reviews identified, unless otherwise specified.

Summary of findings 

The information on the effects of the Mediterranean diet in rheumatoid arthritis is based on one randomized trial [8] that included 51 patients for the outcomes pain, disease activity, functionality, morning stiffness, quality of life and weight. 

The summary of findings is as follows: 

  • Mediterranean diet may make little or no difference to pain in rheumatoid arthritis (low certainty of the evidence).
  • Mediterranean diet may make little or no difference to disease activity in rheumatoid arthritis (low certainty of the evidence).
  • We are uncertain whether Mediterranean diet improves functionality in rheumatoid arthritis as the certainty of the evidence has been assessed as very low. 
  • We are uncertain whether Mediterranean diet improves morning stiffness in rheumatoid arthritis as the certainty of the evidence has been assessed as very low. 
  • We are uncertain whether Mediterranean diet improves quality of life in rheumatoid arthritis as the certainty of the evidence has been assessed as very low. 
  • Mediterranean diet may slightly increase weight in rheumatoid arthritis (certainty of low evidence).

Follow the link to access the interactive version of this table (Interactive Summary of Findings – iSoF)

Other considerations for decision-making

To whom this evidence does and does not apply

  • These results are applicable to patients with rheumatoid arthritis with controlled disease. The population with uncontrolled (active) disease was explicitly excluded from the trial and it is reasonable, from the clinical point of view, to expect a different effect in these cases.
About the outcomes included in this summary
  • The outcomes selected are those considered critical for decision-making by the authors of this summary, among those reported in the analyzed trial. In the case of having had information about other relevant outcomes such as ACR 20 or ACR 70 these would have been incorporated as well.
  • It is important to emphasize that although the effect observed in some outcomes is statistically significant in favor of the Mediterranean diet, the magnitude of the benefit does not exceed the thresholds usually defined to consider the effect clinically relevant. It is not possible to establish whether the Mediterranean diet really has a small but existing effect, or if it is only a spurious finding derived from the methodological limitations of the trial.
Balance between benefits and risks, and certainty of the evidence
  • This is an intervention where the benefits on symptoms and progression of rheumatoid arthritis are uncertain in some outcomes and not clinically relevant in others. 
  • Although the adverse effects of the intervention are minimal, which translates into treatment withdrawal rates due to adverse effects that were not different from the control group [7], it is important to note that a higher final weight was reported.
Resource considerations
  • This intervention has costs associated to both food and the necessary processes to get people to incorporate it efficiently into their lives. For example, in the trial analyzed, a first stage of intensive education was carried out in an in-hospital setting, followed by an out-of-hospital follow-up managed by the health team, including the appropriate food for the study participants. The total cost of implementing an intervention with these characteristics depends to a large extent on whether there are nutritional programs that are responsible for training dietary changes or food provision for patients. 
  • None of the identified studies reported a formal cost or cost-benefit analysis.
What would patients and their doctors think about this intervention
  • When faced with the evidence presented in this summary, most patients and treating physicians should lean against its use. 
  • However, people might be inclined in favor of its use, since there is a positive perception regarding the possible benefits that the Mediterranean diet has on other diseases that are not related to rheumatoid arthritis symptoms and progression (cardiovascular effects, cancer, dementia, among others).

Differences between this summary and other sources

  • The results of this summary are in general in agreement with the reviews analyzed, in terms of the limitations of existing evidence and the associated uncertainty. 
  • Although the conclusions presented by the authors of the trial are concordant with this summary, they are in general more optimistic on interpreting the results, based on the effect on some surrogate outcomes, such as plasma markers of inflammation [8]. 
  • In the main clinical guidelines, such as the American College of Rheumatology 2015 [14] and the European League Against Rheumatism 2016 [15], the Mediterranean diet is not mentioned.
Could this evidence change in the future?
  • The conclusions of this summary are likely to change when new evidence is available, due to the existing uncertainty. 
  • Two relevant randomized trials were identified in the International Clinical Trials Registry Platform of the World Health Organization [16], [17], but their results have not yet been published. These could shed new light on this debate.

How we conducted this summary

Using automated and collaborative means, we compiled all the relevant evidence for the question of interest and we present it as a matrix of evidence.

Follow the link to access the interactive version: Mediterranean diet for rheumatoid arthritis.

Notes

The upper portion of the matrix of evidence will display a warning of “new evidence” if new systematic reviews are published after the publication of this summary. Even though the project considers the periodical update of these summaries, users are invited to comment in Medwave or to contact the authors through email if they find new evidence and the summary should be updated earlier.

After creating an account in Epistemonikos, users will be able to save the matrixes and to receive automated notifications any time new evidence potentially relevant for the question appears.

This article is part of the Epistemonikos Evidence Synthesis project. It is elaborated with a pre-established methodology, following rigorous methodological standards and internal peer review process. Each of these articles corresponds to a summary, denominated FRISBEE (Friendly Summary of Body of Evidence using Epistemonikos), whose main objective is to synthesize the body of evidence for a specific question, with a friendly format to clinical professionals. Its main resources are based on the evidence matrix of Epistemonikos and analysis of results using GRADE methodology. Further details of the methods for developing this FRISBEE are described here (http://dx.doi.org/10.5867/medwave.2014.06.5997)

Epistemonikos foundation is a non-for-profit organization aiming to bring information closer to health decision-makers with technology. Its main development is Epistemonikos database (www.epistemonikos.org).

Potential conflicts of interest

The authors do not have relevant interests to declare.